pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
GLP-1 receptor · news · pharmadog
← back to GLP-1 receptor
News · GLP-1 receptor
341
stories
6h
Significant stock movers of September: Viking soars, Longeveron slides
biospace
16h
Opinion: Energy drinks’ new college sports partnerships make them more dangerous than ever
stat
16h
Opinion: Will Claude ever win a Nobel Prize for medicine?
stat
21h
Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand
biospace
3d
What it’s like to wait for the call from the Nobel Prize committee
stat
3d
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
biospace
3d
#EASD26: Regeneron sees a future combining its obesity drug with lipid-lowering therapy
endpoints
4d
Mistrust in science and a juicy gene-editing lawsuit
stat
4d
3 takeaways from a European obesity scientific meeting
biopharma dive
4d
Fresenius Kabi manufacturing plant hit with FDA warning letter after adverse events
biospace
4d
Zealand dips as Boehringer Ingelheim-partnered weight loss drug fails to impress—again
biospace
4d
#EASD26: Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapy
endpoints
4d
STAT+: Pharmalittle: We’re reading about a plan to lower Medicare drug prices, a Lilly obesity drug, and more
stat
4d
Trump administration appeals ruling blocking limits on international student visas
stat
4d
Opinion: Claude analyzed my genome in 30 minutes. Now we need standards for the results
stat
4d
Opinion: I studied GLP-1 use in children. The results are reassuring
stat
4d
STAT+: Two key Senate health committees face major shake-ups
stat
4d
Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3
fiercebiotech
4d
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
fiercebiotech
5d
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
biospace
5d
STAT+: Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial
stat
5d
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
5d
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
5d
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
fiercebiotech
6d
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
biopharma dive
6d
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
biospace
6d
STAT+: AstraZeneca invests $2 billion in Summit Therapeutics
stat
6d
After GLP-1s, biosimilars are the new frontier in direct-to-employer plans
endpoints
6d
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
biospace
6d
Novo to spend $300M upfront to license Hengrui's weekly oral weight loss drug
endpoints
← prev
page 1 of 12
next →
